Therapeutic inhibition of miR-181a decreased expression of VEGF and MMP1 and suppressed angiogenesis in xenograft tumors, suggesting that targeting miR-181a can be a possible antagomir-based therapy in chondrosarcoma [95]. Here, VEGFA is linked to chondrosarcoma.